Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
hmmmm.purchased 50k of these yesterday to top up for good news in April which will open the door for Bug oil as last. Patient holders to be rewarded soon (12mos rather than years) and the Arysta agreement means they have the patience to see PIM beenfit from growing as a company. Lots of arguments to ramp and deramp, but im holding tight and building hard. Its not that volatile really in the current climate
There does not seem to have been an RNS for this? http://www.wnif.co.uk/articles/868/1/Agrovista-UK-Distribution-deal-for-Plant-Impacts-InCa/Page1.html
interesting report out, see link http://news.yahoo.com/global-biopesticides-market-reach-us-3-4-billion-150018137.html
Difficult to be sure about the lack of support. We have approval for bugoil in the USA but no distributor (ALS pulled out very strangely 2 days before notification). The EU approval is not due until 2013 according to the last update. The company has been at pains to point out that bugoil is not to be a major focus at this stage. It is emphasising the route to profitability lies in the increasing sales of our other products (mainly Inca). Year end is approaching fast and I would hope that a trading update can tell us if we are on track. We have a new management team (both the CFO and CEO have departed, in addition to a new Chairman). They need time to sort it out. Hopefully there is enough cash to do so.
I realised that I did not thank you for those links on Bugoil. Much appreciated (so, not Basil at all then). This was strengthening around 18-19p a while ago. Anyone got any ideas about why the SP is downward with the EU (and others) approvals around the corner. Thanks and Regards, AdJ
You've been in a bit longer than me but I am holding for the long term too.
Have been a holder for over 4 years. Will continue to hold. I have been encouraged by the recent turns of events, although still wary as there has been much promised here that has not come to fruition. This, it must be said, is not the fault of the current BOD. I am optimistic that the new regime will turn this around.
Good research - although the Hardman research is from last May. I assume you are still interested in PIM despite some of your cautious sentiment on this BB? The research shows there are several potential game changers in there (Alathea for example) and points to break even in 2013.
I am enjoying your discussion. Can either of you provide me with a link to further understand bugoil. Which oils are involved, production process etc. I know Basil and not much more. Thanks in advance, AdJ
20th Feb 2012, 10:17 am by Giles Gwinnett Shares in Plant Impact (LON:PIM) went up after it revealed changes in its agreement with Arysta over BugOil, an insect control product, which the company says will improve its cash outlook. The geographic scope of Arysta LifeScience Corporation's exclusive licence of the product has been narrowed and the repayment date of a £750,000 development loan from Arysta which had been due on February 22 this year has now been extended to May 31 in 2013. The firm said it believed the amendments "markedly" improved its financial position and cash flow outlook. "The extension of the Arysta loan provides the company with additional time to achieve regulatory milestones as well as the ability - in the event regulatory milestones are not achieved - to repay the Arysta loan from internal cash generated from the growth in revenues of the company's nutritional product range," it said. The original agreement in 2009 gave Arysta an exclusive worldwide licence to manufacture and sell BugOil, which is based on plant extracts.
Info not meant to be misleading - I was drawing attention to the fact that Bug Oil is only one of the technologies they have been working on. I should have made that clearer.
The information you posted will be 4 years old in May.
That information is very old. And a good example of one of the catastrophic agreements of the past. The deal with Miller appears to have ended in some acrimony, with Blezard explaining that due to 'a lack of support' from the American distributor, sales were abysmal. We no longer trade in America now that Blezard has been binned.
David Dent considers Plant Impact, which is listed on the AIM market of the London Stock Exchange, to be foremost among the companies pursuing what he describes as the “third way” – a combination of ‘green chemistry’ and intelligent design solutions. One of the products developed by David Marks, Chief Technical Officer at Plant Impact, Bug Oil®, is described by Dent as “a brilliantly simple product based on three essential oils working in synergy to provide a very effective preventative and curative pesticide”. Plant Impact recently signed a deal with DVA Agro GmbH for distribution of BugOil® as Bionic™, specifically for ornamental rose production in Tanzania. Other innovative products include InCa, a plant supplement which improves crop product quality by combining a calcium salt with an auxin mimic to ensure the calcium arrives at the part of the plant which needs it most. InCa offers improved fruit quality, longer shelf life and resistance to climate stress. Plant Impact has signed a five year agreement with US based Miller Chemical & Fertilizer Corporation for the distribution of three products including InCa. Field trials on InCa, in conjunction with Miller, have demonstrated significant advantages in fruit crops, notably apples and pears. A Miller field trial, the first field trial conducted using InCa on arable crops, demonstrated a reduction in the negative effects of drought stress on soya crop by increasing the yield by 17.5%, from 2.69 tonnes/hectare to 3.16 tonnes/hectare. According to Dent, Plant Impact’s products “owe their success more to understanding the market need and designing products from basic principles to meet that need as opposed to seeking a magic bullet molecule”.
Distribution deals are all well and good but it's SALES we need. Obviously sales tend to follow on from distribution deals but not always is this the case. Especially here, there have been a good number of distribution deals in the past that have spectactularly failed. The market will be very wary of any distribution deals. I would say that PIM realise this as the last couple have been agreed without any accompanying RNS.
No, I believe it will be distribution news. Mu understanding is that the Arysta connection will underpin this and that Bug Oil will indeed be a viable product. I think the main reason the market did not react is that the last RNS was only part of the jigsaw.
Mr Tea, what good news might that be then? I take it you are not referring to the news that bugoil registration in the US is about to be granted? Because if you read the last notification you will see that it has already been granted, subject to any comments from the general public over a 30 day notice period. The reason the share price has not reacted as it well might have done is because the rights owners appear not to want to do anything with it now, after having waited for over 2 years. The price is depressed because there is still a big question mark over the company's finances. In my view, there is a high rate of cash burn and as yet insufficient generated income.
and how I have been wishing I had sold on the Arysta spike last year. However, things are really falling in place nd this will be back on the radar for a lot of investors. Could be some very good news soon. Se riddler's post for basis of the optimism
Thanks gents
Look at what Arysta paid for the share - 45p. That should be achieved this year on the back of the latest RNS.